Role of paroxetine in interferon--induced immune and behavioural changes in male Wistar rats
Treatment with pro-inflammatory cytokine, IFN alpha was documented to result in neuropsychiatric complications including depression and treatment with antidepressant, paroxetine could improve the depressive symptoms. Therefore, the effects of IFNa on behaviour and cytokine changes in the whole blood culture and in the prefrontal cortex, hypothalamus and hippocampus areas of the brain in Wistar rats were investigated with emphasis on the role of paroxetine in the prevention of depressive behaviour induced by pro-inflammatory cytokines. The group of rats treated with IFNa (s. c. 50 000 IU/kg for 3 days/week for 5 weeks) was compared with three other groups; 1) saline control group (s. c. normal saline 0.2 ml/kg/day for 7 weeks), 2) paroxetine control group (paroxetine suspension orally 10mg/kg/day for 7 weeks) and 3) group treated with paroxetine for 2 weeks followed by IFNa for 5 weeks. In open filed, the IFNa treated rats showed anxiety behaviour compared to the rats from the other groups. There was no significant difference in home cage emergence test, Morris water maze and object recognition test. There is no significant difference in plasma corticosterone between groups. The pro-inflammatory cytokines (TNF alpha, IL1 beta and IFN gamma), were significantly higher whereas the anti-inflammatory cytokine, IL10 was lower in the stimulated whole blood culture of IFN alpha treated rats. In the brain, both pro-inflammatory cytokine IL1 beta and anti-inflammatory cytokine IL10 were higher in hypothalamus of the IFN alpha treated rats; by contrast the concentration of IL10 was lowest in hippocampus region of this group compared to the other groups. The paroxetine pretreated rats did not show these cytokine changes following IFN alpha treatment. Thus it appears that paroxetine pretreatment prevents the pro-inflammatory changes in blood and brain following IFN alpha treatment in turn prevents the anxiety behaviour.
Source (journal)
Journal of psychopharmacology. - Oxford
Oxford : 2007
21:8(2007), p. 843-850
Full text (Publishers DOI)
Publication type
External links
Web of Science
Creation 03.01.2013
Last edited 21.04.2017